Combination therapy shows promise for Hard-to-Treat lymphoma
NCT ID NCT03210662
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with targeted radiation therapy could help patients whose non-Hodgkin lymphoma had returned or stopped responding to treatment. Seventeen adults with aggressive lymphoma types received both treatments. The main goal was to see how many patients responded, with response measured by PET-CT scans. This small study aims to find better options for a difficult-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda) and external beam radiation therapy
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat non-Hodgkin lymphoma that has returned or not responded to prior therapy.
What could go wrong
This was a small, early-phase study with only 17 participants, so results may not apply broadly. The treatment may not work for all lymphoma types and could cause side effects from both radiation and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT T-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States